Zhejiang Jiuzhou Pharm Co Ltd (603456) — Net Asset Quality Index
Zhejiang Jiuzhou Pharm Co Ltd (603456) has a Net Asset Quality Index of 84.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥10.59 Billion minus total liabilities of CN¥1.64 Billion yields net assets of CN¥8.95 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can Zhejiang Jiuzhou Pharm Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Zhejiang Jiuzhou Pharm Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how Zhejiang Jiuzhou Pharm Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 84.6%, representing net assets of CN¥8.95 Billion against total assets of CN¥10.59 Billion CNY. Explore 603456 cash flow metrics to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Zhejiang Jiuzhou Pharm Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for Zhejiang Jiuzhou Pharm Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see how much is Zhejiang Jiuzhou Pharm Co Ltd worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 82.9% | CN¥8.79 Billion | CN¥10.60 Billion | CN¥1.81 Billion | ▲ +5.5 pp |
| 2024 | 77.4% | CN¥8.61 Billion | CN¥11.13 Billion | CN¥2.52 Billion | ▼ -1.3 pp |
| 2023 | 78.6% | CN¥8.53 Billion | CN¥10.85 Billion | CN¥2.32 Billion | ▲ +10.8 pp |
| 2022 | 67.9% | CN¥5.37 Billion | CN¥7.91 Billion | CN¥2.54 Billion | ▲ +2.9 pp |
| 2021 | 65.0% | CN¥4.58 Billion | CN¥7.04 Billion | CN¥2.46 Billion | ▲ +3.3 pp |
| 2020 | 61.7% | CN¥3.09 Billion | CN¥5.00 Billion | CN¥1.92 Billion | ▲ +0.5 pp |
| 2019 | 61.2% | CN¥2.86 Billion | CN¥4.67 Billion | CN¥1.81 Billion | ▼ -22.9 pp |
| 2018 | 84.1% | CN¥2.78 Billion | CN¥3.30 Billion | CN¥526.81 Million | ▼ -1.2 pp |
| 2017 | 85.3% | CN¥2.68 Billion | CN¥3.14 Billion | CN¥461.77 Million | ▼ -0.3 pp |
| 2016 | 85.6% | CN¥2.57 Billion | CN¥3.00 Billion | CN¥432.01 Million | ▲ +10.2 pp |
| 2015 | 75.4% | CN¥2.52 Billion | CN¥3.34 Billion | CN¥819.46 Million | ▲ +3.7 pp |
| 2014 | 71.7% | CN¥1.58 Billion | CN¥2.21 Billion | CN¥624.98 Million | ▲ +24.2 pp |
| 2013 | 47.5% | CN¥736.75 Million | CN¥1.55 Billion | CN¥814.26 Million | ▲ +3.1 pp |
| 2012 | 44.4% | CN¥597.08 Million | CN¥1.34 Billion | CN¥746.26 Million | ▲ +3.1 pp |
| 2011 | 41.4% | CN¥460.54 Million | CN¥1.11 Billion | CN¥653.04 Million | ▲ +1.2 pp |
| 2010 | 40.2% | CN¥343.94 Million | CN¥855.97 Million | CN¥512.03 Million | ▲ +1.4 pp |
| 2009 | 38.8% | CN¥245.87 Million | CN¥634.32 Million | CN¥388.45 Million | ▲ +8.9 pp |
| 2008 | 29.9% | CN¥175.41 Million | CN¥586.69 Million | CN¥411.27 Million | — |